
|Articles|August 28, 2015
New PCSK9 Approval, Biosimilar Cost Tops Specialty Pharmacy Week in Review
Author(s)Davy James, Managing Editor
Top stories of the week on Specialty Pharmacy Times.
Advertisement
[<a href="//storify.com/pharmacytimes/pcsk9-approval-biosimilar-cost" target="_blank">View the story "New PCSK9 Approval, Biosimilar Cost Tops Specialty Pharmacy Week in Review" on Storify</a>]
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
2025 FDA Approvals Highlight the Growing Role of Biomarkers in Breast Cancer
2
SABCS 2025 Roundup: Advancing Therapy and Precision Care in Breast Cancer
3
Ribociclib Plus Fulvestrant Shows Strong PFS and OS Benefits in Patients With Invasive Lobular Carcinoma
4
FDA Approves First At-Home Treatment Device for Depression
5

















































































































































































































